Preparation process of dendritic cell targeted nanoliposome tumor vaccine

Abstract

The invention relates to a preparation process of dendritic cell targeted nanoliposome tumor vaccine and the tumor vaccine can be absorbed and processed targetedly by antigen presenting cells in human body and can be used to induct the antigen presenting cells to mature. The preparation process of the invention comprises the following steps: (1) extracting alpha1 and 3Ga1 glycolipid from rabbit red cell membranes: breaking down the concentrated red cells of the rabbit, mixing cell membranes with chloroform and methanol to react, filtrating to remove granule constitutes, adding double distilled water to obtain oil phase and water phase; collecting water phase and removing methanol and trace chloroform to obtain alpha1-3Ga1-triglyceride composite for standby; and (2) adding a certain amount of alpha1 and 3Ga1 glycolipid in trichloromethane to dissolve, adding the obtained product in a certain amount of yolk lecithin, cholesterol and PEG2000-DSPE mixture, vibrating the obtained mixture for dissolving, performing rotating film evaporation to obtain liposome film, adding PBS buffer solution with 1mg / ml of NY-ESO-1 protein and performing ultrasonic emulsification to obtain the product provided by the invention.

Description

1. Technical field: [0001] The invention relates to a design and preparation process of a medical or experimental vaccine, in particular to a preparation process of a dendritic cell-targeted nano liposome tumor vaccine. 2. Background technology: [0002] Tumor vaccines, as a means of tumor immunotherapy, have attracted much attention and have made great progress in recent years. At present, a variety of tumor vaccines have successfully entered clinical trials, and have achieved certain curative effects in some tumors with strong immunogenicity (such as malignant melanoma and renal cancer, etc.). But overall, the efficacy of current tumor vaccines is far from meeting clinical expectations. The lack of effective processing and presentation of the antigen components in the tumor vaccine by the body's immune cells is one of the problems. In addition, after immature antigen-presenting cells (APCs) capture antigens, if they lack effective immune signal stimulation and fail to mat...

AI Technical Summary

Problems solved by technology

The present invention mainly proposes a new nano-tumor vaccine design strategy on the basis of the existing nano-vaccine technology for how to effectively enhance the capture of tumor vaccines by APCs and how to effectively promote the maturation of APCs at the same time. No similar tumor vaccine design strategy has been reported

Images